Your Second Chance at 10X Gains 🔥

Stocks sold off on Thursday after jobless claims data showed a significant spike in initial jobless claims compared to the previous week. The Dow lost 1.6%, and the S&P 500 fell 1.8%. The Nasdaq underperformed with a 2.0% loss, and the small-cap Russell 2K tumbled 2.8%.

Today, futures are down ahead of another key read on the labor market. The February Jobs Report drops at 8:30 a.m. ET, and S&P 500 futures are down 0.1% in early-morning trading.

Your Second Chance at 10X Gains 🔥

If you missed out on stocks like Tesla, Zoom, and Shopify during the Tech Boom, you're in luck....

Another explosive stock market opportunity could be on the horizon that will could produce a new generation of explosive gainers...

And these stocks could give you a second chance to capture enormous long-term gains.

I've identified some of the most promising stocks on the market, and many of them are available at the lowest prices seen in decades.

Get the Details on My Top Stock Picks Here.

💼 Jobless Claims Spike. Initial jobless claims jumped to 211,000 last week from 190,000 in the previous week. The median forecast called for a top-line figure of 195,000; but the data significantly outpaced estimates and sparked a broad sell off on Thursday.

This tiny biotech stock is on an absolute tear this week.

Unicycive Therapeutics is advancing again in today's premarket, after posting sharp gains for the previous three days.

The rally initially started when Unicycive announced a private placement intended to raise funds for the development of recently-acquired Renazorb.

The stock got another boost on Thursday, when analysts at Maxim and EF Hutton rated the stock as a "buy" with $6 and $5 price targets, respectively.

Last last night, a series of Form 4 filings revealed several company insider had acquired additional shares via a preferred stock conversion.

It seems like nothing can stop UNCY. Shares are up 288.6% this week, and the stock is up 16.0% in today's premarket.

My Take: The rally has been surprisingly resilient. It looks like the market sees some kind of promise in this stock, as it's been steadily building momentum for most of the week.

Barnes & Noble Education is up after a strong earnings report.

The college bookstore operator released its fiscal Q3 2023 earnings report on Thursday evening, and the results surprised analysts.

Barnes & Noble Education reported a loss of $(0.48) per share, missing the Street's estimate of a $(0.07) per share loss by a wide margin.

However, the company's top-line sales figure came in at $447.1 million and easily beat analysts' $397.1 million estimate.

The company also announced its entrance into a sixth amendment to its credit agreement & a first amendment to its term loan credit agreement.

BNED is up 19.1% in today's premarket.

My Take: BNED's big earnings miss is a little disconcerting, especially considering their revenues were much stronger than expected. Share prices recently fell below a positive trend line that had been intact since December. Maybe this rally can help it straighten the ship.

A key drug approval is boosting shares of Molecular Temple.

Late Thursday, the clinical-stage biopharma firm announced the FDA had approved its new drug application for MT-8421 in certain tumor patients.

The approval clears the way for clinical testing of MT-8421 ETB program targeting CTLA-4 in patients with relapsed or refractory solid tumors.

In its press release, Molecular Templates also said it plans to launch a first-in-human Phase 1 study of the drug by mid-2023.

MTEM is one of this morning's top stocks with a 31.9% gain on active premarket trading volume.

My Take: MTEM could be worth watching in the coming weeks. It's been trading sideways since the beginning of February, and MT-8421's continued clinical development could provide several opportunities for additional catalysts.

Bird Global is pushing higher on an earnings beat.

The tiny micro-mobility company reported its Q4 & full-year 2022 results early this morning, and the market likes what it sees.

Bird Global reported quarterly sales of $69.70 million and beat the consensus estimate of $53.38 million by 30.5%.

The company's full-year revenues grew 28% compared to last year, but it reported a substantial operating loss of $(1.21) per share.

BRDS is up 28.6% on active trading volume in the wake of the strong earnings report.

My Take: This was a nice pop for this tiny stock, but I am not exactly sold on this company's long-term outlook. It's nowhere near profitable, and the micro-mobility business is struggling as a whole.

Rlx Technology Inc. Dr [RLX] ...AM
Jinkosolar Holding Company Limited Dr [JKS] ... AM
Buckle, Inc. (The) [BKE] ... AM
Target Hospitality Corp. [TH] ... AM
Genius Sports Limited [GENI] ... AM
The Lion Electric Company [LEV] ... AM
Airsculpt Technologies, Inc. [AIRS] ... AM
Century Casinos, Inc. [CNTY] ... AM
Csi Compressco Lp [CCLP] ... AM
Longeveron Inc. [LGVN] ... AM